Pulmonary Embolism - A Pipeline Analysis Report

Overview of the drug development pipeline for pulmonary embolism  

Pulmonary embolism refers to the blockage of pulmonary artery due to blood clots that travel to the lungs from other parts of the body. It occurs due to deep vein thrombosis (DVT), that occurs due to injury and inactivity. Individuals suffering from pulmonary embolism undergo symptoms such as irregular heartbeat, anxiety, chest pain, weak pulse, and confusion. Medical practitioners prescribe treatments such as surgery or anticoagulants such as warfarin and heparin. According to the CDC, nearly 900,000 people in the US are affected by pulmonary embolism every year, with significant amount of individuals succumbing to the disease. Technavio’s market research analysts identify that 5%-8% of the population in US have genetic risk factors with the genetic defect increasing the risk of pulmonary embolism.  

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the pre-registration, phase III, and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I/II and IND drug development stage.   

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of pulmonary embolism. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

•  EASTON BIOPHARMACEUTICALS
• ESPERO BIOPHARMA
• Verson

Therapeutic assessment of the drug development pipeline for pulmonary embolism by route of administration

• Oral
• Intravenous
• Parenteral
• Inhalation

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the six of total therapeutics molecules for pulmonary embolism are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for pulmonary embolism by therapy

• Small molecules
• Biologicals

According to this pipeline analysis report, six of the molecules that are currently in the drug development pipeline for pulmonary embolism are being developed as small molecules. These molecules are chemically manufactured active substances that bind with specific biological macromolecules and act as an effector and alter the activity of the target cell.

Technavio also offers customization on reports based on specific client requirement.